|
|
Volumn 88, Issue 2, 2013, Pages 368-374
|
|
Second-line therapy in advanced biliary tract cancer: What should be the standard?
a
|
|
Author keywords
Biliary tract cancer; Chemotherapy; Progressive disease; Salvage therapy; Second line therapy
|
|
Indexed keywords
ALBUMIN;
BEVACIZUMAB;
BORTEZOMIB;
CA 19-9 ANTIGEN;
CAPECITABINE;
CELECOXIB;
CETUXIMAB;
CISPLATIN;
DOXORUBICIN;
ERLOTINIB;
EVEROLIMUS;
EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1;
FLUOROPYRIMIDINE DERIVATIVE;
FLUOROURACIL;
GEMCITABINE;
GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;
MITOMYCIN;
OXALIPLATIN;
SORAFENIB;
SUNITINIB;
ADVANCED CANCER;
ANEMIA;
ANOREXIA;
BILIARY TRACT CANCER;
BIOLOGICAL THERAPY;
BLEEDING;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER PROGNOSIS;
CANCER RESISTANCE;
COLORECTAL CANCER;
DIARRHEA;
DRUG DOSE REDUCTION;
DRUG EFFICACY;
DRUG TOLERABILITY;
FATIGUE;
HAND FOOT SYNDROME;
HEAD AND NECK CANCER;
HEAD AND NECK SQUAMOUS CELL CARCINOMA;
HUMAN;
HYPERBILIRUBINEMIA;
HYPERTENSION;
HYPOTENSION;
INFECTION;
KIDNEY CANCER;
LUNG CANCER;
LUNG NON SMALL CELL CANCER;
LYMPHOMA;
METASTATIC COLORECTAL CANCER;
MONOTHERAPY;
MUCOSA INFLAMMATION;
MULTIPLE MYELOMA;
NAUSEA;
NEUROTOXICITY;
NEUTROPENIA;
OVERALL SURVIVAL;
PANCREAS CANCER;
PANCREATIC NEUROENDOCRINE TUMOR;
PROGRESSION FREE SURVIVAL;
REVIEW;
SALVAGE THERAPY;
SIDE EFFECT;
SKIN MANIFESTATION;
SKIN TOXICITY;
STOMATITIS;
THROMBOCYTOPENIA;
THROMBOSIS;
VOMITING;
WEIGHT REDUCTION;
BILIARY TRACT CANCER;
CHEMOTHERAPY;
PROGRESSIVE DISEASE;
SALVAGE THERAPY;
SECOND-LINE THERAPY;
BILIARY TRACT NEOPLASMS;
HUMANS;
NEOPLASM STAGING;
PROGNOSIS;
SALVAGE THERAPY;
STANDARD OF CARE;
|
|
EID: 84885844811
PISSN: 10408428
EISSN: 18790461
Source Type: Journal
DOI: 10.1016/j.critrevonc.2013.05.010 Document Type: Review |
|
Times cited : (17)
|
|
References (76)
|
